{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:34:04Z","timestamp":1792427644538,"version":"4.5.0"},"reference-count":155,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jtha.2025.09.021","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:09:43Z","timestamp":1760144983000},"page":"26-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Thrombolytic drugs for ischemic stroke: historical perspective, state of play, and future developments"],"prefix":"10.1016","volume":"24","author":[{"given":"Bamlaku Enawgaw","family":"Walie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph E.","family":"Hagemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6714-9131","authenticated-orcid":false,"given":"Be\u2019eri","family":"Niego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.09.021_bib1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2141.2005.05444.x","article-title":"Molecular mechanisms of fibrinolysis","volume":"129","author":"Cesarman-Maus","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.09.021_bib2","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/jcbfm.2014.99","article-title":"Plasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis?","volume":"34","author":"Niego","year":"2014","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.jtha.2025.09.021_bib3","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood.2020008951","article-title":"Plasminogen: an enigmatic zymogen","volume":"137","author":"Keragala","year":"2021","journal-title":"Blood"},{"issue":"4 Suppl","key":"10.1016\/j.jtha.2025.09.021_bib4","doi-asserted-by":"crossref","first-page":"136S","DOI":"10.1378\/chest.97.4_Supplement.136S","article-title":"Thrombolytic therapy in acute myocardial infarction","volume":"97","author":"Rutherford","year":"1990","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.09.021_bib5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1089-2516(98)80275-8","article-title":"The role of thrombolytic therapy in pulmonary embolism","volume":"1","author":"Thorpe","year":"1998","journal-title":"Tech Vasc Interv Radiol"},{"key":"10.1016\/j.jtha.2025.09.021_bib6","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/S0049-3848(09)70145-8","article-title":"Thrombolytic therapy for deep vein thrombosis: potential application of plasmin","volume":"123","author":"Marder","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.09.021_bib8","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","article-title":"Tissue plasminogen activator for acute ischemic stroke","volume":"333","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.09.021_bib9","doi-asserted-by":"crossref","first-page":"12a","DOI":"10.1016\/0002-9149(92)91168-4","article-title":"Clinical risks of thrombolytic therapy","volume":"69","author":"Califf","year":"1992","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jtha.2025.09.021_bib10","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","article-title":"Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke","volume":"359","author":"Hacke","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.09.021_bib11","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(98)08020-9","article-title":"Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators","volume":"352","author":"Hacke","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.09.021_bib12","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/S0140-6736(12)60768-5","article-title":"The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial","volume":"379","author":"Sandercock","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.09.021_bib13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1084\/jem.58.4.485","article-title":"The fibrinolytic activity of hemolytic streptococci","volume":"58","author":"Tillett","year":"1933","journal-title":"J Exp Med"},{"key":"10.1016\/j.jtha.2025.09.021_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1172\/JCI102046","article-title":"The effect in patients of streptococcal fibrinolysin (streptokinase) and streptococcal desoxyribonuclease on fibrinous, purulent, and sanguineous pleural exudations","volume":"28","author":"Tillett","year":"1949","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtha.2025.09.021_bib16","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/159779a0","article-title":"Fibrinolytic activity of normal urine","volume":"159","author":"MacFarlane","year":"1947","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2025.09.021_bib18","first-page":"768","article-title":"Guest MM Urokinase-an activator of plasma profibrinolysin extracted from urine","volume":"171","author":"Sobel","year":"1952","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jtha.2025.09.021_bib19","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/0735-1097(89)90493-2","article-title":"The origin of thrombolytic therapy","volume":"14","author":"Sherry","year":"1989","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2025.09.021_bib22","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1161\/ATVBAHA.108.179655","article-title":"The tissue-type plasminogen activator story","volume":"29","author":"Collen","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2025.09.021_bib23","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/301214a0","article-title":"Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli","volume":"301","author":"Pennica","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2025.09.021_bib33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1749-6632.1957.tb42627.x","article-title":"The use of plasmin in humans","volume":"68","author":"Cliffton","year":"1957","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jtha.2025.09.021_bib34","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1177\/1747493019840938","article-title":"Extending the time window for intravenous thrombolysis in acute ischemic stroke using magnetic resonance imaging-based patient selection","volume":"14","author":"Ringleb","year":"2019","journal-title":"Int J Stroke"},{"key":"10.1016\/j.jtha.2025.09.021_bib35","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJMoa2310392","article-title":"Tenecteplase for stroke at 4.5 to 24 hours with perfusion-imaging selection","volume":"390","author":"Albers","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.09.021_bib36","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1001\/jama.2024.14721","article-title":"Tenecteplase vs alteplase for patients with acute ischemic stroke: the ORIGINAL randomized clinical trial","volume":"332","author":"Meng","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2025.09.021_bib37","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1474-4422(24)00377-6","article-title":"Tenecteplase versus alteplase for acute stroke within 4\u00b75 h of onset (ATTEST-2): a randomised, parallel group, open-label trial","volume":"23","author":"Muir","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtha.2025.09.021_bib38","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1474-4422(24)00206-0","article-title":"Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4\u00b75 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial","volume":"23","author":"Parsons","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtha.2025.09.021_bib39","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa2402980","article-title":"Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy","volume":"391","author":"Xiong","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.09.021_bib40","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0140-6736(99)07403-6","article-title":"Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial","volume":"354","author":"Van De Werf","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.09.021_bib41","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM198403083101001","article-title":"Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction","volume":"310","author":"Van de Werf","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.09.021_bib42","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1474-4422(17)30253-3","article-title":"Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial","volume":"16","author":"Logallo","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtha.2025.09.021_bib43","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1001\/jama.1995.03530130023023","article-title":"Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)","volume":"274","author":"Hacke","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2025.09.021_bib44","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1161\/STROKEAHA.115.009917","article-title":"Safety and tolerability of desmoteplase within 3 to 9 hours after symptoms onset in japanese patients with ischemic stroke","volume":"46","author":"Mori","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.09.021_bib45","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1474-4422(15)00047-2","article-title":"DIAS-3 Investigators Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"14","author":"Albers","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtha.2025.09.021_bib46","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1161\/STROKEAHA.116.013715","article-title":"Desmoteplase 3 to 9 hours after major artery occlusion stroke: the DIAS-4 trial (efficacy and safety study of desmoteplase to treat acute ischemic stroke)","volume":"47","author":"von Kummer","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.09.021_bib47","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJMoa1716405","article-title":"Tenecteplase versus alteplase before thrombectomy for ischemic stroke","volume":"378","author":"Campbell","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.09.021_bib48","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1056\/NEJMoa1804355","article-title":"MRI-guided thrombolysis for stroke with unknown time of onset","volume":"379","author":"Thomalla","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.09.021_bib49","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0140-6736(22)02600-9","article-title":"Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial","volume":"401","author":"Wang","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.09.021_bib50","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1161\/STROKEAHA.124.048375","article-title":"Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection: the CHABLIS-T II randomized clinical trial","volume":"56","author":"Cheng","year":"2025","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.09.021_bib51","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2025.12063","article-title":"Alteplase for acute ischemic stroke at 4.5 to 24 hours: the HOPE randomized clinical trial","volume":"334","author":"Zhou","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2025.09.021_bib52","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1056\/NEJMoa1813046","article-title":"Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke","volume":"380","author":"Ma","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.09.021_bib53","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jama.2020.1511","article-title":"Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke: the EXTEND-IA TNK part 2 randomized clinical trial","volume":"323","author":"Campbell","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2025.09.021_bib54","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/291590a0","article-title":"Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus","volume":"291","author":"Matsuo","year":"1981","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2025.09.021_bib55","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa1109842","article-title":"A randomized trial of tenecteplase versus alteplase for acute ischemic stroke","volume":"366","author":"Parsons","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.09.021_bib56","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/svn-2021-000978","article-title":"Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study","volume":"7","author":"Li","year":"2022","journal-title":"Stroke Vasc Neurol"},{"key":"10.1016\/j.jtha.2025.09.021_bib57","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0140-6736(81)91217-4","article-title":"Specific lysis of an iliofemoral thrombus by administration of extrinsic (tissue-type) plasminogen activator","volume":"2","author":"Weimar","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.09.021_bib58","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(22)01054-6","article-title":"Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial","volume":"400","author":"Menon","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.09.021_bib59","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S1474-4422(22)00124-7","article-title":"Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial","volume":"21","author":"Kvistad","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtha.2025.09.021_bib60","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S1474-4422(22)00171-5","article-title":"Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial","volume":"21","author":"Bivard","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtha.2025.09.021_bib61","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1474-4422(22)00484-7","article-title":"Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial","volume":"22","author":"Roaldsen","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtha.2025.09.021_bib15","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev.pa.25.040185.002213","article-title":"The current and future use of thrombolytic therapy","volume":"25","author":"Sherry","year":"1985","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jtha.2025.09.021_bib17","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3181\/00379727-81-19983","article-title":"An activator of plasminogen in normal urine","volume":"81","author":"Astrup","year":"1952","journal-title":"Proc Soc Exp Biol Med"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2025.09.021_bib20","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1538-7836.2011.04370.x","article-title":"Historical perspective and future direction of thrombolysis research: the re-discovery of plasmin","volume":"9","author":"Marder","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.021_bib21","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1172\/JCI107246","article-title":"Increased plasminogen activator (urokinase) in tissue culture after fibrin deposition","volume":"52","author":"Bernik","year":"1973","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtha.2025.09.021_bib24","first-page":"397","article-title":"Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI)","volume":"1","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.09.021_bib25","first-page":"65","article-title":"GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico","volume":"336","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.09.021_bib26","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1161\/01.CIR.94.6.1233","article-title":"One-year results from the global utilization of streptokinase and TPA for occluded coronary arteries (GUSTO-I) trial","volume":"94","author":"Califf","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.09.021_bib27","first-page":"349","article-title":"ISIS-2 (Second International Study of Infarct Survival) Collaborative Group, Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2","volume":"2","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.09.021_bib28","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0140-6736(88)92656-6","article-title":"Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET)","volume":"2","author":"Wilcox","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.09.021_bib29","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0140-6736(90)90663-P","article-title":"Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.09.021_bib62","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1212\/WNL.42.5.976","article-title":"Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke","volume":"42","author":"Mori","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.jtha.2025.09.021_bib63","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1001\/jama.282.21.2019","article-title":"Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke","volume":"282","author":"Clark","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2025.09.021_bib64","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1161\/01.STR.31.4.811","article-title":"The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators","volume":"31","author":"Clark","year":"2000","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.09.021_bib65","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1474-4422(08)70044-9","article-title":"Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial","volume":"7","author":"Davis","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtha.2025.09.021_bib66","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1161\/STROKEAHA.109.572040","article-title":"Phase IIB\/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial","volume":"41","author":"Haley","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.09.021_bib67","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S1474-4422(15)70017-7","article-title":"Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study","volume":"14","author":"Huang","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtha.2025.09.021_bib68","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/svn-2023-002820","article-title":"Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection: the umbrella phase IIa CHABLIS-T randomised clinical trial","volume":"9","author":"Cheng","year":"2024","journal-title":"Stroke Vasc Neurol"},{"key":"10.1016\/j.jtha.2025.09.021_bib30","series-title":"Approves Genentech\u2019s TNKase\u00ae in Acute Ischemic Stroke in Adults","author":"Genentech","year":"2025"},{"key":"10.1016\/j.jtha.2025.09.021_bib32","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1097\/MS9.0000000000001385","article-title":"Mechanical thrombectomy for AIS from large vessel occlusion - current trends and future perspectives","volume":"85","author":"Parvathy","year":"2023","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.jtha.2025.09.021_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2005.09.003","article-title":"Plasminogen activators: a comparison","volume":"44","author":"Baruah","year":"2006","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.jtha.2025.09.021_bib70","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/21655979.2016.1229718","article-title":"The evolution of recombinant thrombolytics: current status and future directions","volume":"8","author":"Adivitiya","year":"2017","journal-title":"Bioengineered"},{"key":"10.1016\/j.jtha.2025.09.021_bib71","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1001\/jama.1984.03350100044028","article-title":"Anaphylactic reactivity to streptokinase","volume":"252","author":"McGrath","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2025.09.021_bib72","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1515\/bchm2.1982.363.2.1155","article-title":"The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain","volume":"363","author":"G\u00fcnzler","year":"1982","journal-title":"Hoppe Seylers Z Physiol Chem"},{"key":"10.1016\/j.jtha.2025.09.021_bib73","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1515\/bchm2.1982.363.2.1043","article-title":"The complete amino acid sequence of low molecular mass urokinase from human urine","volume":"363","author":"Steffens","year":"1982","journal-title":"Hoppe Seylers Z Physiol Chem"},{"key":"10.1016\/j.jtha.2025.09.021_bib74","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S1089-2516(98)80223-0","article-title":"Urokinase: past, present, and future","volume":"1","author":"Sasahara","year":"1998","journal-title":"Tech Vasc Interv Radiol"},{"key":"10.1016\/j.jtha.2025.09.021_bib75","article-title":"Outcomes and treatment complications of intravenous urokinase thrombolysis in acute ischemic stroke in China","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.jtha.2025.09.021_bib76","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0741-5214(95)70045-5","article-title":"Comparison of streptokinase, urokinase, and recombinant tissue plasminogen activator in an in vitro model of venous thrombolysis","volume":"22","author":"Ouriel","year":"1995","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jtha.2025.09.021_bib77","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1254\/jphs.FP0050872","article-title":"Effects of intra-arterial urokinase on a non-human primate thromboembolic stroke model","volume":"100","author":"Susumu","year":"2006","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.jtha.2025.09.021_bib78","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1161\/01.STR.17.4.638","article-title":"The beneficial effect of intracarotid urokinase on acute stroke in a baboon model","volume":"17","author":"Del Zoppo","year":"1986","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.09.021_bib79","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1161\/STROKEAHA.118.022606","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.09.021_bib80","doi-asserted-by":"crossref","first-page":"I","DOI":"10.1177\/2396987321989865","article-title":"European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke","volume":"6","author":"Berge","year":"2021","journal-title":"Eur Stroke J"},{"key":"10.1016\/j.jtha.2025.09.021_bib82","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0140-6736(19)31053-0","article-title":"Extending thrombolysis to 4\u00b75-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data","volume":"394","author":"Campbell","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.09.021_bib83","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.csbj.2019.06.023","article-title":"Structural biology and protein engineering of thrombolytics","volume":"17","author":"Mican","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.jtha.2025.09.021_bib84","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1161\/STROKEAHA.114.008247","article-title":"Time-dependent thrombus resolution after tissue-type plasminogen activator in patients with stroke and mice","volume":"46","author":"Kim","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.09.021_bib85","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood.2020008913","article-title":"Neutrophil extracellular traps promote tPA-induced brain hemorrhage via cGAS in mice with stroke","volume":"138","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.09.021_bib86","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3340\/jkns.2022.0120","article-title":"Recanalization rate and clinical outcomes of intravenous tissue plasminogen activator administration for large vessel occlusion stroke patients","volume":"66","author":"Lee","year":"2023","journal-title":"J Korean Neurosurg Soc"},{"key":"10.1016\/j.jtha.2025.09.021_bib87","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1212\/01.wnl.0000250341.38014.d2","article-title":"Recanalization after thrombolysis in stroke patients","volume":"68","author":"Zangerle","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jtha.2025.09.021_bib88","doi-asserted-by":"crossref","first-page":"12382","DOI":"10.1016\/S0021-9258(17)39036-1","article-title":"Primary structure of single-chain pro-urokinase","volume":"260","author":"Kasai","year":"1985","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jtha.2025.09.021_bib89","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1182\/blood.V87.9.3545.bloodjournal8793545","article-title":"Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1","volume":"87","author":"Higazi","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.09.021_bib90","doi-asserted-by":"crossref","first-page":"17375","DOI":"10.1074\/jbc.270.29.17375","article-title":"Enhancement of the enzymatic activity of single-chain urokinase plasminogen activator by soluble urokinase receptor","volume":"270","author":"Higazi","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jtha.2025.09.021_bib91","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1182\/blood.V67.5.1215.1215","article-title":"Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect","volume":"67","author":"Pannell","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.09.021_bib92","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ejphar.2017.11.026","article-title":"Effect of human recombinant prourokinase(rhpro-UK) on thromboembolic stroke in rats","volume":"818","author":"Hao","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jtha.2025.09.021_bib93","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1182\/blood.V73.7.1864.1864","article-title":"The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro","volume":"73","author":"Lijnen","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.09.021_bib94","first-page":"77","article-title":"Effect of recombinant human prourokinase on thrombolysis in a rabbit model of thromboembolic stroke","volume":"8","author":"Hao","year":"2018","journal-title":"Biomed Rep"},{"key":"10.1016\/j.jtha.2025.09.021_bib95","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/01.STR.29.1.4","article-title":"PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke","volume":"29","author":"del Zoppo","year":"1998","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.09.021_bib96","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.282.21.2003","article-title":"Intra-arterial prourokinase for acute ischemic strokethe PROACT II study: a randomized controlled trial","volume":"282","author":"Furlan","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2025.09.021_bib97","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s12975-022-01012-9","article-title":"Efficacy and safety of recombinant human prourokinase in acute ischemic stroke: a phase IIa randomized clinical trial","volume":"13","author":"Song","year":"2022","journal-title":"Transl Stroke Res"},{"key":"10.1016\/j.jtha.2025.09.021_bib98","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40263-023-01051-2","article-title":"Thrombolysis with recombinant human prourokinase 4.5\u20136 h after acute ischemic stroke: a phase IIa, randomized, and open-label multicenter clinical trial","volume":"38","author":"Song","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jtha.2025.09.021_bib99","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.25415","article-title":"Efficacy and safety of recombinant human prourokinase in the treatment of acute ischemic stroke within 4.5 hours of stroke onset: a phase 3 randomized clinical trial","volume":"6","author":"Song","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtha.2025.09.021_bib100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1474-4422(24)00436-8","article-title":"Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4.5 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial","volume":"24","author":"Li","year":"2025","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.jtha.2025.09.021_bib101","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamaneurol.2024.4688","article-title":"Prourokinase vs Standard Care for Patients With Mild Ischemic Stroke: The PUMICE Randomized Clinical Trial","volume":"82","author":"Xiong","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jtha.2025.09.021_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2025.108300","article-title":"Tenecteplase versus alteplase in patients with acute ischemic stroke: An updated meta-analysis of randomized controlled trials","volume":"34","author":"Sheraz","year":"2025","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jtha.2025.09.021_bib103","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/23969873221150022","article-title":"European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke","volume":"8","author":"Alamowitch","year":"2023","journal-title":"Eur Stroke J"},{"key":"10.1016\/j.jtha.2025.09.021_bib104","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1476-5381.2011.01514.x","article-title":"Desmoteplase: discovery, insights and opportunities for ischaemic stroke","volume":"165","author":"Medcalf","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jtha.2025.09.021_bib105","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1161\/01.STR.0000149938.08731.2c","article-title":"The Desmoteplase in Acute Ischemic Stroke Trial (DIAS)","volume":"36","author":"Hacke","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.09.021_bib106","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/01.STR.0000217403.66996.6d","article-title":"Dose escalation of desmoteplase for acute ischemic stroke (DEDAS)","volume":"37","author":"Furlan","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.09.021_bib107","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1474-4422(08)70267-9","article-title":"Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study","volume":"8","author":"Hacke","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtha.2025.09.021_bib108","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1056\/NEJMoa2400314","article-title":"Reteplase versus alteplase for acute ischemic stroke","volume":"390","author":"Li","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.09.021_bib109","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/STROKEAHA.123.045193","article-title":"Safety and efficacy of reteplase versus alteplase for acute ischemic stroke: a phase 2 randomized controlled trial","volume":"55","author":"Li","year":"2024","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.09.021_bib110","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1093\/oxfordjournals.eurheartj.a014716","article-title":"ESPRIT: a European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction","volume":"17","author":"Malcolm","year":"1996","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.09.021_bib111","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1053\/euhj.2000.2498","article-title":"Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction","volume":"21","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.09.021_bib112","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1253\/circj.CJ-12-0091","article-title":"Observational investigation of thrombolysis with the tissue-type plasminogen activator monteplase for acute pulmonary embolism in Japan","volume":"76","author":"Niwa","year":"2012","journal-title":"Circ J"},{"key":"10.1016\/j.jtha.2025.09.021_bib113","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s11033-019-05167-x","article-title":"Bacterial staphylokinase as a promising third-generation drug in the treatment for vascular occlusion","volume":"47","author":"Nedaeinia","year":"2020","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.jtha.2025.09.021_bib114","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1160\/TH03-07-0435","article-title":"Clot penetration and fibrin binding of amediplase,a chimeric plasminogen activator (K2 tu-PA)","volume":"91","author":"Rijken","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.021_bib115","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1474-4422(21)00210-6","article-title":"Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4\u00b75 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial","volume":"20","author":"Gusev","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtha.2025.09.021_bib116","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.448","article-title":"Efficacy of SMTP-7, a small-molecule anti-inflammatory thrombolytic, in embolic stroke in monkeys","volume":"6","author":"Suzuki","year":"2018","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.jtha.2025.09.021_bib117","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1538-7836.2009.03701.x","article-title":"Direct fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potential","volume":"8","author":"Marder","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.021_bib118","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.celrep.2012.02.012","article-title":"The X-ray crystal structure of full-length human plasminogen","volume":"1","author":"Law","year":"2012","journal-title":"Cell Rep"},{"key":"10.1016\/j.jtha.2025.09.021_bib119","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1055\/s-0037-1616127","article-title":"Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit","volume":"86","author":"Marder","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.021_bib120","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jvir.2009.03.043","article-title":"Locally applied recombinant plasmin results in effective thrombolysis in a porcine model of arteriovenous graft thrombosis","volume":"20","author":"Hoefer","year":"2009","journal-title":"J Vasc Interv Radiol"},{"issue":"10 Suppl","key":"10.1016\/j.jtha.2025.09.021_bib121","first-page":"S45","article-title":"Thrombolysis with plasmin: implications for stroke treatment","volume":"41","author":"Marder","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.09.021_bib122","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1538-7836.2008.02969.x","article-title":"A first-in-human phase I trial of locally delivered human plasmin for hemodialysis graft occlusion","volume":"6","author":"Shlansky-Goldberg","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.021_bib123","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1538-7836.2012.04728.x","article-title":"Safety of catheter-delivered plasmin in patients with acute lower extremity arterial or bypass graft occlusion: phase I results","volume":"10","author":"Marder","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.021_bib124","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.09.022","article-title":"Plasmin (human) administration in acute middle cerebral artery ischemic stroke: phase 1\/2a, open-label, dose-escalation, safety study","volume":"26","author":"Mitchell","year":"2017","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jtha.2025.09.021_bib125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217234","article-title":"Site-specific PEGylation of micro-plasmin for improved thrombolytic therapy through engineering enhanced resistance against serpin mediated inhibition","volume":"14","author":"Kaur","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2025.09.021_bib126","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jacc.2011.02.049","article-title":"Stroke intervention: catheter-based therapy for acute ischemic stroke","volume":"58","author":"White","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2025.09.021_bib127","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/0049-3848(90)90406-3","article-title":"Regulation of plasmin, miniplasmin, and streptokinase-plasmin complex by alpha 2-antiplasmin, alpha 2-macroglobulin, and antithrombin III in the presence of heparin","volume":"59","author":"Anonick","year":"1990","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.09.021_bib128","first-page":"725","article-title":"Alpha 2-macroglobulin is the primary inhibitor of miniplasmin in vitro and in vivo in the mouse. Comparison with alpha 2-antiplasmin in simultaneous reaction experiments","volume":"255","author":"Gonias","year":"1988","journal-title":"Biochem J"},{"key":"10.1016\/j.jtha.2025.09.021_bib129","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.thromres.2008.01.007","article-title":"The thrombolytic effect of miniplasmin in a canine model of femoral artery thrombosis","volume":"122","author":"Fu","year":"2008","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.09.021_bib130","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1161\/01.STR.0000028267.09604.7B","article-title":"Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits","volume":"33","author":"Lapchak","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.09.021_bib131","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1046\/j.1538-7836.2003.00078.x","article-title":"Recombinant human microplasmin: production and potential therapeutic properties","volume":"1","author":"Nagai","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.021_bib132","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1161\/01.STR.0000140628.00927.1a","article-title":"Microplasmin reduces ischemic brain damage and improves neurological function in a rat stroke model monitored with MRI","volume":"35","author":"Suzuki","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.09.021_bib133","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/j.1538-7836.2004.00889.x","article-title":"Comparative effects of microplasmin and tissue-type plasminogen activator (tPA) on cerebral hemorrhage in a middle cerebral artery occlusion model in mice","volume":"2","author":"Suzuki","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.021_bib134","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1148\/radiol.2442061316","article-title":"Microplasmin and tissue plasminogen activator: comparison of therapeutic effects in rat stroke model at multiparametric MR imaging","volume":"244","author":"Chen","year":"2007","journal-title":"Radiology"},{"key":"10.1016\/j.jtha.2025.09.021_bib135","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1161\/STROKEAHA.109.560201","article-title":"Randomized, placebo-controlled, dose-ranging clinical trial of intravenous microplasmin in patients with acute ischemic stroke","volume":"40","author":"Thijs","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.09.021_bib136","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3390\/toxins2040793","article-title":"Fibrolase: trials and tribulations","volume":"2","author":"Markland","year":"2010","journal-title":"Toxins"},{"key":"10.1016\/j.jtha.2025.09.021_bib137","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/01.RVI.0000167863.10122.2A","article-title":"A phase I trial of alfimeprase for peripheral arterial thrombolysis","volume":"16","author":"Ouriel","year":"2005","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jtha.2025.09.021_bib138","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1200\/JCO.2006.05.8438","article-title":"Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices","volume":"24","author":"Moll","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtha.2025.09.021_bib139","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jvs.2009.08.053","article-title":"Efficacy and safety of alfimeprase in patients with acute peripheral arterial occlusion (PAO)","volume":"51","author":"Han","year":"2010","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jtha.2025.09.021_bib140","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1055\/s-2007-969033","article-title":"Single-chain antibodies as new antithrombotic drugs","volume":"33","author":"Hagemeyer","year":"2007","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2025.09.021_bib141","doi-asserted-by":"crossref","first-page":"19717","DOI":"10.1016\/S0021-9258(18)55051-1","article-title":"Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single-chain urokinase","volume":"266","author":"Holvoet","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jtha.2025.09.021_bib142","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1432-1033.1992.tb17499.x","article-title":"Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase","volume":"210","author":"Holvoet","year":"1992","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.jtha.2025.09.021_bib143","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/blood.V81.3.696.696","article-title":"Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase","volume":"81","author":"Holvoet","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.09.021_bib144","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1161\/01.CIR.87.3.1007","article-title":"Thrombolytic profiles of clot-targeted plasminogen activators. Parameters determining potency and initial and maximal rates","volume":"87","author":"Holvoet","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.09.021_bib145","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1432-1033.1989.tb15095.x","article-title":"Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin","volume":"185","author":"Dewerchin","year":"1989","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.jtha.2025.09.021_bib146","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1161\/01.CIR.82.5.1744","article-title":"Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model","volume":"82","author":"Collen","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.09.021_bib147","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1055\/s-0038-1656344","article-title":"Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase","volume":"68","author":"Dewerchin","year":"1992","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.021_bib148","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood.V78.4.1005.1005","article-title":"Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo","volume":"78","author":"Dewerchin","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.09.021_bib149","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1161\/CIRCRESAHA.114.302514","article-title":"Towards effective and safe thrombolysis and thromboprophylaxis: preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets","volume":"114","author":"Wang","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.jtha.2025.09.021_bib150","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/bloodadvances.2021006691","article-title":"Platelet-targeted thrombolysis for treatment of acute ischemic stroke","volume":"7","author":"Palazzolo","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.09.021_bib151","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004535","article-title":"Novel thrombolytic drug based on thrombin cleavable microplasminogen coupled to a single-chain antibody specific for activated GPIIb\/IIIa","volume":"6","author":"Bonnard","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jtha.2025.09.021_bib152","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1182\/blood.V71.4.831.831","article-title":"The platelet membrane glycoprotein IIb-IIIa complex","volume":"71","author":"Phillips","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.09.021_bib153","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s12975-022-01107-3","article-title":"Effects of the new thrombolytic compound LT3001 on acute brain tissue damage after focal embolic stroke in rats","volume":"15","author":"Jiang","year":"2024","journal-title":"Transl Stroke Res"},{"key":"10.1016\/j.jtha.2025.09.021_bib154","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/cvr\/cvae060","article-title":"A low bleeding risk thrombolytic agent: citPA5","volume":"120","author":"Chen","year":"2024","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jtha.2025.09.021_bib155","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1055\/s-0039-3399568","article-title":"Applications of nanotechnology in the diagnosis and therapy of stroke","volume":"46","author":"Landowski","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2025.09.021_bib156","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1602336","article-title":"Neutrophil extracellular traps in central nervous system disorders: mechanisms, implications, and emerging perspective","volume":"16","author":"Qiao","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2025.09.021_bib157","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood-2015-08-662650","article-title":"ADAMTS13-mediated thrombolysis of t-PA-resistant occlusions in ischemic stroke in mice","volume":"127","author":"Denorme","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.09.021_bib158","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3390\/ijms25020891","article-title":"Neuroprotection during thrombectomy for acute ischemic stroke: a review of future therapies","volume":"25","author":"Dammavalam","year":"2024","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625006130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625006130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T08:06:21Z","timestamp":1768464381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625006130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":155,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1538783625006130"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.09.021","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombolytic drugs for ischemic stroke: historical perspective, state of play, and future developments","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}